GlassScriptPhysician profile
Luqman Dabiri
NPI 1114159159
$1,725.37
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $718.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.93 | 2019-2020 | |
| Lilly USA, LLC | $245.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.63 | 2019-2020 | |
| Amgen INC. | $184.24 | 2019-2020 | |
| Glaxosmithkline, LLC. | $156.10 | 2019 | |
| Pfizer INC. | $121.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $99.97 | 2019 | |
| Ge Healthcare | $67.31 | 2020 | |
| Amarin Pharma, INC. | $61.19 | 2019-2020 | |
| Novo Nordisk INC | $27.73 | 2020 | |
| Merck Sharp & Dohme LLC | $11.86 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.29 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luqman Dabiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.